Seagen announces FDA approval for Adcetris in new indication

Seagen (SGEN) announced that the Food and Drug Administration has approved Adcetris for the treatment of pediatric patients two years and older with previously untreated high risk classical Hodgkin lymphoma, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide. Seagen and Takeda (TAK) jointly develop Adcetris. Under the terms of the collaboration agreement, Seagen has U.S. and Canadian commercialization rights, and Takeda has rights to commercialize Adcetris in the rest of the world.